Jakarta (ANTARA) – Since its founding 100 years ago, insulin innovation has continued to be developed. One of the newest is IDegAsp’s 2-in1 Insulin Co-Formulation innovation, which is expected to simplify insulin therapy for people with diabetes.
“Patients need a simpler therapeutic procedure. Currently 2-in-1 insulin co-formulation is an innovation that can meet the needs of patients and can help millions of diabetics in Indonesia,” said Chairman of the Indonesian Endocrinology Association (PERKENI), Prof. Dr. dr. Ketut Suastika, Sp.PD-KEMD, in a media discussion event “Novo Nordisk: Experience the Freedom with Co-formulation Insulin”, Thursday.
Diabetes itself is a major health problem in Indonesia, which is now one of the ten countries with the highest number of diabetics in the world in 2019. The number of diabetics is expected to increase and there is a need for interventions to prevent and manage diabetes.
Also read: Moringa leaves, an alternative that can be used to treat diabetes
Also read: Blindness due to diabetes can be prevented
To address Indonesia’s growing number of diabetic patients, health experts have developed guidelines for preventing and managing the disease.
In managing diabetes, PERKENI has determined that a patient’s HbA1c level should reach 7 percent. Unfortunately, more than 70 percent of diabetes patients in Indonesia do not meet this target due to complex procedures.
Patients undergoing insulin therapy usually need more than one injection of insulin per day to maintain blood sugar properly.
Complex therapeutic procedures can decrease patient adherence rates and lead to failure to lower targeted HbA1c levels.
To overcome these challenges, the 2-in-1 insulin co-formulation IDegAsp provides a simpler procedure for patients to undergo.
Prof. Suastika said that IDegAsp is the first and only 2-in-1 insulin co-formulation in the world that contains insulin degludec new generation basalt and insulin aspart in one injection.
The innovative 2-in-1 insulin co-formulation IDegAsp is designed to simplify insulin therapy so that it is easier to live, with only one injection a day and requires no re-suspension.
This innovation is also safe because it has a low risk of hypoglycemia and has been shown to lower HbA1c levels and control blood sugar after meals. The 2-in-1 insulin co-formulation IDegAsp is an easier option for insulin therapy.
“At Novo Nordisk, we are constantly working to develop products that address the key challenges faced by diabetes patients and physicians. We have a long history of changing the diabetes landscape and we are constantly innovating to deliver patient-centered solutions,” said Novo’s Vice President & General Manager. Nordisk Indonesia, Anand Shetty.
In addition, the advantages of 2-in-1 insulin co-formulation IDegAsp are expected to facilitate treatment and improve compliance with T2DM patients.
The 2-in-1 insulin co-formulation IDegAsp, which is now available for National Health Insurance patients, is expected to have a positive impact on diabetes care in Indonesia.
Also read: Obese people do not have diabetes, but are they safe from other diseases?
Also read: Living with diabetes during the COVID-19 pandemic
Also read: Benefits of cherries, protect from diabetes to lower cholesterol
Reporter: Arnidhya Nur Zhafira
Editor: Maria Rosari Dwi Putri
COPYRIGHT © BETWEEN 2021
–
